Some uncommon and perhaps surprising applications of common treatments are in the works.
RAD 2025: What You May Have Missed
Explore key insights from the 2025 Revolutionizing Atopic Dermatitis meeting, featuring expert interviews and the latest treatment advancements.
The Weekly Dose: Cannabis, Contraceptives, and Advances in Alzheimer Disease and Gonorrhea Treatment
Clinical insights on cannabis and dementia, hormonal contraceptives and postpartum depression, the FDA-approved blood test for Alzheimer disease, more.
Novo's GLP-1/Amylin Dual Agonist Amycretin to Enter Late-Stage Trials for Obesity
Both oral and subcutaneous formulations of the long-acting GLP-1 and amylin receptor agonist move into stage 3 clinical trials following positive feedback from regulators.
The Weekly Dose: Advancements in Colonoscopy, AI for Mammography, and Telemedicine Antibiotic Stewardship
Discover the latest breakthroughs in clinical research, from at-home cancer screening to AI advancements in mammography, shaping future healthcare practices.
GLP-1s May Cut Obesity-Related Cancer Risk: Daily Dose
Your daily dose of the clinical news you may have missed.
Q&A: JAK Inhibitor Safety in Context and the Rich Atopic Dermatitis Pipeline, with Leon Kircik, MD
RAD 2025: Renowned AD investigator Kircik provides the history behind the class-wide black box warning, highlights JAK inhibitor efficacy, and toplines exciting AD research.